Autogenous Injectable Bone for Regeneration with Mesenchymal Stem Cells and Platelet-Rich Plasma: Tissue-Engineered Bone Regeneration

Yamada, Yoichi; Naiki, Takahito; Takahashi, M; Hata, Ken‐ichiro; Nagasaka, Tetsuro

doi:10.1089/1076327041348284

Cited by 288 publications

(219 citation statements)

References 21 publications

Supporting

Mentioning

210

Contrasting

Unclassified

Order By: Relevance

“…Yamada et al [52] demonstrated in dogs that the combination of MSC and PLG resulted in a significantly higher maturation of bone and neovasularization than observed in control subjects. Thereafter, the same group used a combination of MSC and PLG for successful clinical alveolar bone augmentation [47].…”

Section: Tissue Engineeringmentioning

confidence: 99%

The use of autologous platelet–leukocyte gels to enhance the healing process in surgery, a review

et al. 2007

View full text Add to dashboard Cite

Background: The therapeutic use of autologously prepared, platelet-leukocyte-enriched gel (PLG) is a relatively new technology for the stimulation and acceleration of soft tissue and bone healing. The effectiveness of this procedure lies in the delivery of a wide range of platelet growth factors mimicking the physiologic wound healing and reparative tissue processes. Despite an increase in PLG applications, the structures and kinetics of this autogenously derived biologic material have not been observed. Methods: A review of the most recent literature was performed to evaluate the use of PLG in various surgical disciplines. Results: The review showed that the application of PLG has been extended to various surgical disciplines including orthopedics, cardiac surgery, plastic and maxillofacial surgery, and recently also endoscopic surgery. Conclusion: This review demonstrates the usefulness of PLG in a wide range of clinical applications for improvement of healing after surgical procedures.Key words: Growth factors -Leukocytes -Platelet gel -Wound healing Soft tissue wound healing and bone growth involve physiologic cascades in which cellular and hormonal factors play pivotal roles [1,2]. Some of these cascade components can be isolated from autologously drawn whole blood. Point-of-care devices can intraoperatively fractionate the autologous blood into platelet-poor plasma, platelet-leukocyte-rich plasma (P-LRP), and red blood cells [3,4]. The P-LRP fraction, a mixture of concentrated platelets and leukocytes, can be activated by (autologous) thrombin to create a viscous solution known as platelet-leukocyte gel (PLG). This platelet coagulum can be exogenously applied to soft wound tissues, bone, or synthetic bone as a spray or as a solid, clotted, gelatinous mass. The rationale for applying platelet gel is based on the delivery of platelet growth factors to tissues and on the fact that platelet a-granules, found inside the platelets, contain a variety of growth factors [5]. Platelet gel growth factors are peptides that promote cell proliferation, differentiation, chemotaxis, and the migration of various cells involved in both wound healing and bone growth [6,7].Recently, numerous P-LRP devices have become available for therapeutic use to stimulate and accelerate soft tissue and bone healing and to control postoperative wound bleeding. The rationale for applying PLG lies in the mimicking and accelerating of physiologic wound healing and reparative tissue processes.This article provides information on the results of electron microscopic imaging used to evaluate the content of PLG. Furthermore, because the use of PLG is a relatively new per-and/or perioperative biotechnological application, new and additional indications for the use of PLG are defined. New PLG applications are reviewed for different applications including cardiac surgery, general surgery, orthopedics and traumatology, cosmetic surgery, maxillofacial surgery, sports medicine, and endoscopic surgical procedures. Defining platelet-leukocyte-rich...

show abstract

Section: Tissue Engineeringmentioning

confidence: 99%

The use of autologous platelet–leukocyte gels to enhance the healing process in surgery, a review

et al. 2007

View full text Add to dashboard Cite

show abstract

“…The growth factors from the platelet-rich plasma, which can be used in a clinical setting, have been shown to positively affect the proliferation of MSCs (Lucarelli et al, 2003) and are thought to play a role in their osteogenic differentiation (Intini, 2009). When combined with biomaterials and cells, platelet-rich plasma has also been shown to promote bone formation in heterotopic sites (Bi et al, 2010;Kasten et al, 2008;Yamada et al, 2004). Studies to determine the time required to culture the MSCs as aggregates in order to optimise the amount of bone formed in vivo are performed so as to make the system more clinically feasible.…”

Section: Introductionmentioning

confidence: 99%

Cell aggregation enhances bone formation by human mesenchymal stromal cells

Chatterjea

LaPointe²,

Barradas

et al. 2017

eCM

View full text Add to dashboard Cite

The amount of bone generated using current tissue engineering approaches is insufficient for many clinical applications. Previous in vitro studies suggest that culturing cells as 3D aggregates can enhance their osteogenic potential, but the effect on bone formation in vivo is unknown. Here, we use agarose wells to generate uniformly sized mesenchymal stromal cell (MSC) aggregates. When combined with calcium phosphate ceramic particles and a gel prepared from human platelet-rich plasma, we generated a tissue engineered construct that significantly improved in vivo bone forming capacity as compared to the conventional system of using single cells seeded directly on the ceramic surface. Histology demonstrated the reproducibility of this system, which was tested using cells from four different donors. In vitro studies established that MSC aggregation results in an up-regulation of osteogenic transcripts. And finally, the in vivo performance of the constructs was significantly diminished when unaggregated cells were used, indicating that cell aggregation is a potent trigger of in vivo bone formation by MSCs. Cell aggregation could thus be used to improve bone tissue engineering strategies.

show abstract

“…Moreover, the addition of platelet-rich plasma (PRP), which includes various growth factors (Marx et al, 1988) and offers osteoinductive properties (Kanno et al, 2005), contributes to cellular proliferation, matrix formation, collagen synthesis, osteoid production, and other processes that accelerate tissue regeneration. In terms of using these autologous materials, tissue engineering for bone regeneration has been shown to be an attractive alternative to autogenous or synthetic bone substitutes (Ito et al, 2006;Yamada et al, 2004;Buser et al, 1990). It has the additional advantage of using the host as a donor source, which avoids bone graft donor site morbidity.…”

Section: Discussionmentioning

confidence: 99%

The role of bone marrow aspirate cells in the management of atrophic mandibular fractures by mini-invasive surgical approach: Single-institution experience

Mannelli

Arcuri

Conti

et al. 2017

Journal of Cranio-Maxillofacial Surgery

View full text Add to dashboard Cite

Elderly patients management Bone marrow aspirate cells Min-invasive surgical approach a b s t r a c t Purpose: The treatment of fractures involves addressing the biology of fracture repair and the mechanical stability of fracture fixation. Traditionally it has included the addition of bone graft to enhance healing. New advances in the understanding of the cellular and molecular mechanisms of fracture repair have led to the use of growth factors to accelerate bone healing. This study aimed to assess the advantages of autologous stem cell use for atrophic mandibular fracture treatment in comparison to standard technique. Materials and methods: A total of 35 patients (14 male and 21 female) were treated for fractures of atrophic mandibles between January 2011 and December 2014. Surgical technique provided miniinvasive open reduction with or without immediate homologous bone graft, while selected patients received autologous bone marrow aspirate cell grafts in addition to the standard treatment. Demographic data and details of treatment and outcomes were recorded. Results: Patients were categorized according to the use of autologous stem cells, leaving 17 patients treated with standard technique and autologous stem cells (Group A) and 18 treated with standard osteosynthesis only (Group B). Of the 35 patients, 26 had bilateral fractures; most patients had significant medical co-morbidities. Immediate bone graft was used in 37.1% of patients (7 in group A and 6 in group B). Complications occurred in 5 patients (14.3%). Two patients in group B (11.1%) showed non-union of the fracture. One patient in group A (5.8%) and one patient in group B (5.5%) showed wound dehiscence and were treated conservatively; one patient in group B had a local infection (5.5%), one out of 35 (2.8%), that was managed by prolonged antibiotic treatment. Conclusions: Despite the advanced age and medical co-morbidities of the vast majority of patients, miniinvasive open approach with autologous bone graft ensures a fast and excellent recovery. Moreover, the management of atrophic mandibular fractures by bone marrow aspirate cells is a safe and useful procedure which has a lower complication rate when compared to standard technique.

show abstract

Autogenous Injectable Bone for Regeneration with Mesenchymal Stem Cells and Platelet-Rich Plasma: Tissue-Engineered Bone Regeneration

Cited by 288 publications

References 21 publications

The use of autologous platelet–leukocyte gels to enhance the healing process in surgery, a review

The use of autologous platelet–leukocyte gels to enhance the healing process in surgery, a review

Cell aggregation enhances bone formation by human mesenchymal stromal cells

The role of bone marrow aspirate cells in the management of atrophic mandibular fractures by mini-invasive surgical approach: Single-institution experience

Contact Info

Product

Resources

About